Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2021
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study
Sebastian Bauer, Michael C Heinrich, Suzanne George, et al.
BMC Cancer
|
December 13, 2022
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
Patrick Schöffski, Suzanne George, Michael C Heinrich, et al.
The Oncologist
|
July 27, 2021
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study
John R Zalcberg, Michael C Heinrich, Suzanne George, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2022
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
Sebastian Bauer, Robin L Jones, Jean-Yves Blay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Michael C Heinrich, Jean-Yves Blay, Hans Gelderblom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2024
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib
Hans Gelderblom, Albiruni A Razak, Matthew H Taylor, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study
Hans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.
Nature Medicine
|
January 5, 2024
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
Michael C Heinrich, Robin L Jones, Suzanne George, et al.
Lancet (London, England)
|
June 6, 2024
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hans Gelderblom, Vivek Bhadri, Silvia Stacchiotti, et al.
Cancer Cell
|
May 16, 2019
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Bryan D Smith, Michael D Kaufman, Wei-Ping Lu, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 10, 2021
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous <i>KIT/PDGFRA</i> Mutations in the Phase III INVICTUS Study
Sebastian Bauer, Michael C Heinrich, Suzanne George, et al.
BMC Cancer
|
December 13, 2022
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
Patrick Schöffski, Suzanne George, Michael C Heinrich, et al.
The Oncologist
|
July 27, 2021
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study
John R Zalcberg, Michael C Heinrich, Suzanne George, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2022
Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial
Sebastian Bauer, Robin L Jones, Jean-Yves Blay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 23, 2025
Updated Overall Survival and Long-Term Safety With Ripretinib Versus Sunitinib in Patients With GI Stromal Tumor: Final Overall Survival Analysis From INTRIGUE
Michael C Heinrich, Jean-Yves Blay, Hans Gelderblom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 12, 2024
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib
Hans Gelderblom, Albiruni A Razak, Matthew H Taylor, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 20, 2023
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study
Hans Gelderblom, Robin L Jones, Jean-Yves Blay, et al.
Nature Medicine
|
January 5, 2024
Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial
Michael C Heinrich, Robin L Jones, Suzanne George, et al.
Lancet (London, England)
|
June 6, 2024
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Hans Gelderblom, Vivek Bhadri, Silvia Stacchiotti, et al.
Cancer Cell
|
May 16, 2019
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants
Bryan D Smith, Michael D Kaufman, Wei-Ping Lu, et al.
Page
of 5